Furthermore, CD44 was upregulated upon TGFB1-induced EMT (40), and our study reported overexpression of TGFB1 in aggressive prostate cancer (3.41-fold in GE and ∼2-fold protein). The gene discussed is CD44; the disease is prostate carcinoma.